Clinical Research Section
Richard T. Davey, Jr., M.D.
Chief, Clinical Research Section; NIAID Deputy Clinical Director
Provides direct clinical care to patients at NIH Clinical Center
Major Areas of Research
- Emerging Infectious Diseases of Public Health Importance
In addition to ongoing clinical research interests in the area of HIV-1 therapeutics and the immunopathogenesis of HIV-1 infection, since 2006 Dr. Davey’s clinical research team in the Clinical Research Section (CRS) of LIR has also been actively involved in clinical trials of novel anti-influenza therapeutics, as well as observational studies of novel subtypes of seasonal or pandemic influenza. This has included leadership and active participation in the observational and interventional studies conducted through the INSIGHT Influenza network as well as the design and implementation of interventional trials (IRC 002 and IRC 005 being the most recent trials) being conducted through the Intramural Research Collaboration sponsored by the Division of Clinical Research, NIAID.
Phase I/II studies both of promising antiviral agents as well as immune-based therapies have been part of this initiative. In addition, CRS has played an active role in the development and testing of novel medical countermeasures involved in either prophylaxis or treatment of Ebola virus infection, as well as orchestrated the care at the NIH Clinical Research Center of health care workers occupationally exposed to that agent during the recent West African outbreak. In this regard, Dr. Davey is 1) the Principal Investigator of the PREPARE trial studying the role of a booster dose of the Merck Ebola vaccine in HCWs or laboratory workers at risk of occupational exposure to Ebola, and 2) was the U.S. Principal Investigator on the PALM study of 4 different medical countermeasures against Ebola Zaire that was conducted in the Democratic Republic of the Congo in 2019 and led to the licensure of two different monoclonal antibody products active against this infection. In 2020 his section within LIR turned its attention to the testing of novel therapeutics against SARS-CoV-2 infection and participated in a number of randomized clinical trials studying COVID-19 cases.
M.D., 1980, Columbia University College of Physicians and Surgeons, New York, NY
Dr. Davey received his M.D. from the Columbia University College of Physicians and Surgeons in 1980. He completed his internship and internal medicine residency at Boston University Hospital in 1983. He came to NIH as a fellow in NIAID’s Infectious Diseases training program and received board certification in ID in 1986. He joined the Laboratory of Immunoregulation in 1987 as an attending physician in the NIAID/CCMD HIV Research clinic. In addition, he is deputy clinical director within NIAID and also serves as the medical director of the Special Clinical Studies Unit at the Clinical Center.
Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ; PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J; PALM Consortium Study Team. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019 Dec 12;381(24):2293-2303. *
Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns CB, Shoham S, Deville JG, Feucht E, Feinberg J, Luke T, Raviprakash K, Danko J, O'Neil D, Metcalf JA, King K, Burgess TH, Aga E, Lane HC, Hughes MD, Davey RT; IRC002 Study Team. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017 Jun 5(6):500-511.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 Jan 26;376(4):330-341.
PREVAIL II Writing Group.; Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvey D. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016 Oct 13;375(15):1448-1456.
Davey Jr. RT, Markowitz N, Beigel J, Wentworth D, Babiker A, Rehman T, Dewar R, Metcalf J, Uyeki T, Finley EB, Standridge B, Riska P, Lane HC, Gordin F, Neaton JD on behalf of the INSIGHT FLU005 IVIG Pilot Study Group. INSIGHT FLU005: An Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study. J Infect Dis. 2016 Feb 15;213(4). pii: jiv453. [Epub ahead of print].
Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One. 2013;8(2):e57121.
Sherrie Walls – Program Specialist
Colleen Hadigan – Staff Clinician
Jocelyn Voell – Supervisory Nurse Specialist
Megan Anderson – Nurse Specialist
Holly Baus – Nurse Specialist
Gabriella Diaz – Nurse Specialist
Cheryl Chairez – Nurse Specialist
Mary McLaughlin – Nurse Specialist
Catherine Rehm – Biologist
Julia Aepfelbacher – Post Bacc IRTA
Chloe Chaudhury – Post Bacc IRTA
16-I-0053: Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure, NCT02788227